Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aromatase Inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Chemotherapy | ACTIVE_COMPARATOR | Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. |
| Chemotherapy and Bevacizumab | EXPERIMENTAL | Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks. |
| Endocrine Therapy | ACTIVE_COMPARATOR | Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks. |
| Endocrine Therapy and Bevacizumab | EXPERIMENTAL | Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Aromatase Inhibitor | DRUG | Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks. |
| Bevacizumab | DRUG | Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks. |
| Epirubicine | DRUG | Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks. |
| 5-Fluorouracil (5FU) | DRUG | Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks. |
| Cyclophosphamide | DRUG | Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks. |
| Paclitaxel | DRUG | Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks. |
| Docetaxel | DRUG | Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks. |
Inclusion Criteria: * Histologically or cytologically confirmed, HER2-negative, men or pre- or post-menopausal women with primary operable adenocarcinoma of the breast, greater than or equal to (\>=) 2.5 centimeters (cm) in size * Eastern Cooperative Oncology Group (ECOG)/world health organization ...
Top 20 of 92 competitors
Aromatase Inhibitor is an investigational small molecule being studied for the treatment of breast cancer. It is currently in Phase 2 clinical development. The drug is being evaluated in combination with other treatment regimens for patients with primary HER2 negative breast cancer.
Aromatase Inhibitor is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational oncology drug for the treatment of breast cancer.
Aromatase Inhibitor is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, with no active trials currently ongoing.
Aromatase Inhibitor has been studied in one completed Phase 2 clinical trial, identified as NCT00773695. This trial evaluated the drug in combination with neoadjuvant treatment regimens in participants with primary HER2 negative breast cancer. The trial enrolled 150 participants in Norway.
Aromatase Inhibitor is not the same as Avastin. The clinical trial NCT00773695 studied Aromatase Inhibitor in combination with bevacizumab (Avastin) and other neoadjuvant treatment regimens for HER2 negative breast cancer. Aromatase Inhibitor is a distinct investigational drug being developed by Roche.